TNF and rheumatoid arthritis: Under these circumstances, the medical team decided to start a therapeutical approach using rituximab (chimeric monoclonal antibody), plus hydroxychloroquine, the combination of the two drugs being advised in the cases of adult patients’ treatment for severe/active RA and an intolerance or inappropriate response to other DMARDs or TNF-targeted drugs.